GESULLO, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 940
EU - Europa 706
AS - Asia 238
AF - Africa 8
SA - Sud America 1
Totale 1.893
Nazione #
US - Stati Uniti d'America 934
RU - Federazione Russa 355
IT - Italia 165
SG - Singapore 66
CN - Cina 64
IE - Irlanda 58
HK - Hong Kong 50
SE - Svezia 45
CH - Svizzera 35
JO - Giordania 24
TW - Taiwan 16
IN - India 13
DE - Germania 11
FR - Francia 8
CI - Costa d'Avorio 7
ES - Italia 7
CA - Canada 6
FI - Finlandia 6
GB - Regno Unito 5
AT - Austria 4
JP - Giappone 2
KR - Corea 2
NL - Olanda 2
RO - Romania 2
BR - Brasile 1
EG - Egitto 1
MY - Malesia 1
PL - Polonia 1
SI - Slovenia 1
UA - Ucraina 1
Totale 1.893
Città #
Santa Clara 239
Fairfield 89
Chandler 70
Dublin 58
Ashburn 55
Woodbridge 43
Singapore 42
Cambridge 40
Wilmington 40
Seattle 39
Houston 37
Bern 35
Hong Kong 33
Florence 29
Altamura 24
Lawrence 22
Beijing 18
Princeton 16
Taipei 14
Ann Arbor 13
New York 12
Buffalo 11
Moscow 11
Mumbai 11
Boston 8
Bremen 8
Medford 8
Rome 8
Shanghai 8
Abidjan 7
Barcelona 7
Fiesole 7
Kent 7
Boardman 6
Milan 6
Pian di Scò 6
San Diego 6
Los Angeles 5
Toronto 5
Dearborn 4
Paris 4
Vienna 4
Faenza 3
Fontebuona 3
Genoa 3
London 3
Andover 2
Bologna 2
Chennai 2
Cortona 2
Falls Church 2
Ferrara 2
Gambettola 2
Helsinki 2
Lappeenranta 2
Le Vigan 2
Livorno 2
New Taipei 2
Pantigliate 2
Pavia 2
Sachigaoka 2
San Gavino Monreale 2
San Jose 2
Seoul 2
Siena 2
Villa Minozzo 2
Washington 2
West Jordan 2
Atlanta 1
Azzano Decimo 1
Baotou 1
Bari 1
Brescia 1
Böblingen 1
Cairo 1
Campi Bisenzio 1
Fuzhou 1
Hillsboro 1
Iasi 1
Imperia 1
Islington 1
Jacksonville 1
Jinan 1
Kilburn 1
Leawood 1
Ljubljana 1
Lugo di Vicenza 1
Malo 1
Montréal 1
Nanjing 1
Nantong 1
Ngau Wu Tok 1
Norwalk 1
Olgiate Comasco 1
Piacenza 1
Prato 1
Rimini 1
Rozzano 1
Saviano 1
Sesto Fiorentino 1
Totale 1.203
Nome #
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 161
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 149
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 144
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 125
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 124
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 117
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 102
Validation of the Mayo alliance prognostic system for mastocytosis 99
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 90
Prognotic Impact of Mutations in Systemic Mastocytosis 85
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 78
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 76
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 75
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 71
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 68
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 68
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 61
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 59
Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management 51
Diagnostic and therapeutic challenges in mast cell sarcoma 51
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 41
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 16
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 14
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 11
Totale 1.936
Categoria #
all - tutte 6.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.873


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020182 0 0 0 0 28 31 32 28 26 13 14 10
2020/2021115 6 12 3 39 4 5 2 2 15 12 12 3
2021/202295 0 0 16 1 0 4 0 20 1 2 19 32
2022/2023424 25 72 27 22 22 53 41 19 59 12 18 54
2023/2024285 18 18 29 20 38 26 16 56 7 20 19 18
2024/2025775 41 115 91 225 303 0 0 0 0 0 0 0
Totale 1.936